UVax 2129
Alternative Names: 1c-SApNP vaccine - Ufovax; Coronavirus vaccine - Ufovax; UVax-2129Latest Information Update: 28 Jun 2024
Price :
$50 *
At a glance
- Originator The Scripps Research Institute
- Developer The Scripps Research Institute; Uvax Bio
- Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 11 Nov 2021 Scripps Research has patents pending for the 1C-SApNP platform technology and individual vaccines in USA (UVax Bio website, November 2021)
- 03 Nov 2021 Immunogenicity data from preclinical studies in COVID-2019 infections (Prevention) released by UVax Bio